Reuters logo
BRIEF-FDA approves Vectibix for use in wild-type RAS metastatic colorectal cancer
June 29, 2017 / 9:40 PM / in 4 months

BRIEF-FDA approves Vectibix for use in wild-type RAS metastatic colorectal cancer

June 29 (Reuters) - Amgen Inc:

* FDA approves Vectibix® (panitumumab) for use in wild-type RAS metastatic colorectal cancer

* Amgen Inc - ‍U.S. Fda approved supplemental biologics license application for vectibix for patients with wild-type RAS metastatic colorectal cancer​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below